Systemic sclerosis & Raynaud's
Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification
Main finding · 5-year cancer incidence (hematologic and solid-organ)Result — go to the resultHazard ratio 1.17 95% CI 1.11–1.23Authors' conclusion
Patients with SSc demonstrate significantly increased risks for both hematologic and solid-organ cancers, with risk profiles varying by autoantibody status.
Study context
- Population
- Adults with systemic sclerosis (SSc) and matched controls with seborrheic keratosis, EMR from 128 health care organizations, 2014–2024; stratified by autoantibody status (RNA polymerase III, anticentromere, anti-Scl-70) when availableadults with SSc
- Participants
- 66,637 adults
- Exposure
- SSc vs matched controls with seborrheic keratosis
- SScn = 66,637
- Outcome
- Five-year incidences of hematologic and solid-organ cancers
- Follow-up
- Five years
Methodological detailsmatched controls, electronic medical records from 128 health care organizations, Cox proportional hazards regression
- Matched controls
- Electronic medical records from 128 health care organizations
- Cox proportional hazards regression
Main finding
As reported in the abstract
5-year cancer incidence (hematologic and solid-organ) · 5 years
Hazard ratio
1.17
95% CI 1.11–1.23
SScvs Controls
HR 1.17 (95% CI 1.11–1.23)
- Hematologic cancer, SSc vs controls: HR (95% CI 1.50-1.88), significantly increased
- 1.68
- Solid-organ cancer, SSc vs controls: HR
- 1.23 (95% CI 1.16-1.31)
Observational data: associations, not effects.
Further findings
Specific hematologic cancers, SSc vs controls · 5 years
- Multiple myeloma: HR
- 2.13 (95% CI 1.61-2.81)
- Myelodysplastic syndromes: HR
- 2.03 (95% CI 1.49-2.77)
Specific solid-organ cancers, SSc vs controls · 5 years
- Esophageal cancer (highest risk): HR
- 3.96 (95% CI 2.36-6.65)
- Lung cancer: HR
- 2.32 (95% CI 2.00-2.69)
Cancer risk by autoantibody subgroup · 5 years
- Anti-Scl-70 positive, overall cancer: HR
- 1.40 (95% CI 1.03-1.92)
- RNA polymerase III positive, hematologic cancers: HR
- 2.20 (95% CI 1.10-4.28)
- Anticentromere positive: no increased cancer risks
Original publication
Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification. Arthritis Rheumatol. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →